Rajeev Saggar Sells 1,649 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 1,649 shares of the business’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $13.68, for a total value of $22,558.32. Following the sale, the insider now directly owns 211,672 shares in the company, valued at $2,895,672.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liquidia Trading Down 3.1 %

Shares of LQDA stock opened at $12.55 on Thursday. Liquidia Co. has a 1-year low of $5.71 and a 1-year high of $16.99. The company has a market capitalization of $954.18 million, a price-to-earnings ratio of -10.46 and a beta of 0.16. The stock’s fifty day simple moving average is $14.60 and its 200-day simple moving average is $11.18.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The firm had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $5.29 million. On average, sell-side analysts predict that Liquidia Co. will post -1.01 EPS for the current year.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of recent analyst reports. HC Wainwright boosted their target price on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Liquidia in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Liquidia by 1.0% in the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after purchasing an additional 26,678 shares in the last quarter. Kynam Capital Management LP grew its stake in Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after purchasing an additional 698,324 shares in the last quarter. Vestal Point Capital LP purchased a new position in Liquidia in the fourth quarter valued at about $12,331,000. Beryl Capital Management LLC purchased a new position in Liquidia in the third quarter valued at about $3,135,000. Finally, LB Partners LLC purchased a new position in Liquidia in the fourth quarter valued at about $3,404,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).